摘要
目的:研究红花多糖(SPS)对荷S180肉瘤BALB/c小鼠肿瘤转移相关基因CD44、MMP-9、TIMP-1、AMFmRNA及nm23-H1蛋白含量的影响,观察SPS对血管生成及抗肿瘤的作用,进一步探讨SPS抑制肿瘤转移作用及其机制。
方法:
1.Real Time PCR法检测BALB/c小鼠肿瘤组织CD44、MMP-9. TIMP-1、AMFmRNA的表达情况
2.Western blot法检测肿瘤组织中nm23-H1蛋白表达情况。
3.鸡胚绒毛尿囊膜实验观察血管生成数量及面积的变化。
4.免疫组化法检测小鼠肿瘤组织VEGF蛋白及MVD的变化。
5.ELISA法检测荷瘤小鼠血清中IL-12、IL-10及TNF-α的含量
结果:
1.Real Time PCR检测发现,SPS作用于荷瘤小鼠后,肿瘤组织中CD44、MMP-9、AMF mRNA的表达下降,TIMP-1mRNA的表达升高
2.Western blot检测发现,经SPS作用后小鼠肿瘤组织中nm23-H1蛋白含量上升。
3.SPS中剂量组干预后鸡胚绒毛尿囊膜上血管生成数目和面积较模型对照组减少(P<0.05),SPS高剂量组较模型对照组显著减少(P<0.01)。
4.免疫组化法检测发现,SPS中剂量组小鼠肿瘤组织中VEGF阳性表达率明显下降(与模型组比较P<0.01),MVD降低极其明显(P<0.001);SPS高剂量组小鼠肿瘤组织中VEGF阳性表达率及MVD降低极其明显(P<0.001)。
5.ELISA法检测发现,与模型对照组相比较,SPS中、高剂量组小鼠血清中IL-12和TNF-α含量升高极其明显(P<0.001);IL-10含量下降极其显著(P<0.001)。
结论:
1.SPS能够抑制小鼠肿瘤组织CD44、MMP-9、AMF mRNA的表达,促进TIMP-1mRNA的表达,在肿瘤转移的黏附、降解、运动环节上抑制肿瘤的转移。
2.SPS能够促进小鼠肿瘤组织nm23-H1的表达,抑制肿瘤的转移
3.SPS具有抑制鸡胚绒毛尿囊膜上血管生成的作用。
4.SPS能够通过抑制VEGF的表达抑制荷瘤小鼠肿瘤组织血管的生成,降低MVD,使肿瘤生长及转移受到抑制。
5.SPS能够通过提高IL-12的表达,降低IL-10的表达调整Th1/Th2漂移,并促进TNF-α表达。
Objective:To study the SPS which has an effect on BALB/c mice bearing S180tumor metastasis related genes CD44、MMP-9、 TIMP-1、AMF mRNA and nm23-H1protein, to observe the SPS on angiogenesis and anti-tumor effect, to explore the SPS refrain tumor metastasis and its mechanism furthermore.
Methods:
1. Detect the CD44and MMP-9, TIMP-1, AMF mRNA expression of BALB/c mice tumor tissue by Real Time PCR assay
2. Detect the expression of nm23-H1protein of tumor tissue by Western blot assay.
3. Chicken embryos chorioallantoic membrane assay to observe angiogenesis number and size of the change.
4. Immunohistochemical assay to detect the mice tumor tissue VEGF protein and MVD changes.
5. ELISA assay to detect serum IL-12, IL-10and TNF-α content.
Results:
1. Real Time PCR detection,the SPS role in tumor-bearing mice, tumor tissue of CD44、MMP-9、AMF mRNA expression was decreased and TIMP-1mRNA expression was increased.
2. Western blot analysis found that the nm23-H1protein content increased in the tumor tissue of mice with the reaction of the SPS.
3. SPS mid-dose group after the intervention of the SPS in the chicken embryos chorioallantoic membrane angiogenesis, the number and size compared with the model control group decreased (P<0.05),SPS high-dose group compared with the model control group was significantly reduced (P<0.01)
4. Immunohistochemical methods detected the SPS mid-dose groups VEGF expression in tumor tissue was significantly decreased (compared with model group P<0.01), MVD reduction is extremely obvious (P<0.001); VEGF positive expression rates and MVD reduction in the SPS high-dose group of mice tumor tissue are extremely clear (P<0.001)
5. ELISA examination found that compared with the model group, the mid-dose, high dose of the serum IL-12and TNF-α levels increased very significantly (P<0.001), IL-10decreased very significantly (P<0.001)
Conclusion:
1. SPS can inhibit tumor tissue of mice CD44, MMP-9, the AMF mRNA expression, promote TIMP-1mRNA expression. SPS can inhibit the adhesion, degradation, and motion of tumor metastasis.
2. SPS can restrain tumor metastasis by promoting the expression of nm23-H1in tumor tissue of mice
3. SPS can inhibit the generation of the chicken embryos chorioallantoic membrane vascular.
4. By inhibiting VEGF expression and reducing MVD, SPS can restrain the growth of blood vessels in the tumor tissue, make tumor growth and transfer under control.
5. SPS can increase the expression of IL-12, reducing the expression of IL-10to adjust the Th1/Th2shift, and to promote TNF-α expression.
引文
[1]冀振华,赵平主编.肿瘤临床综合治疗新概念[M].清华大学出版社2006,7.
[2]Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden:globocan 2000 [J]. Int J Cancer,2001,94(2):153-156.
[3]李天舒.我国癌症谱呈现新特点[N].健康报,2010-05-28(1).
[4]郑海霞,周清华,中东兰,等.nm23-H1基因对肺癌细胞株恶性表型的逆转作用[J].现代肿瘤医学,2011,19(6): 1055-1057.)
[5]陈止堂主编.临床肿瘤学概论[M].中国协和医科大学出版社,2000.
[6]郑荣寿,张思维,吴良有,等.中国肿瘤登记地区2008年恶性肿瘤发病和死亡分析[J].中国肿瘤,2012,21(1):1-12.
[7]嵇玉峰,吴江平,邓伟明.吴维城主任医师治疗恶性肿瘤学术思想[J].中医研究,2011,24(12):57-60
[8]丁小文,郑树,彭佳萍.人参皂甙Rg3对实验性小鼠大肠肿瘤的预防作用[J].中华肿瘤防治杂志,2006,13(1):19-22.
[9]中海涛,张祥宏,郑末,等.经口给予黄芩提取物对H22肝癌荷瘤小鼠影响的实验研究[J].中国肿瘤临床,2006,33(14):821-824.
[10]刘强,陈兴兴,孙学刚,等.甘草黄酮对荷瘤S180小鼠免疫细胞数量的影响[J].中华中医药杂志,2007,22(12):904-906.
[11]张世蘋,周翌婧,刘艳,等.甘草黄酮诱导肝癌SMMC-7721细胞凋亡及其对相关蛋白survivin表达的影响[J].南京医科大学学报:自然科学版,2008,28(3)330-334.
[12]李建昌, 于南荣,黄志良. 中医扶正固本法对结直肠癌新辅助化疗患者免疫功能的影响[J].广西医学,2008,30(9)1313-1314.
[13]冀振华,赵平主编.肿瘤临床综合治疗新概念[M].清华大学出版社,2006,7:356-357
[14]陈世伟,张利民主编.肿瘤中西医综合治疗[M].人民卫生出版社,2001.
[15]高捷.甲皱微循环检查在肿瘤治疗中的应用[J].中日友好医院学 报,1996,11(4):319-322.
[16]刘成煌,姚亚其.胸部恶性肿瘤患者的甲皱微循环表现[J].中华肿瘤杂志,1984,8(4):250.
[17]陈建民.癌症患者血液高黏度状态与活血化瘀治疗[J].中西医结合杂志,1985,5(2):89-91.
[18]李国贤,吴浩源,李冰芳,等.从体外血栓形成的血小板黏附性探讨血瘀与癌症[J].中西医结合杂志,1987,7(12):726.
[19]王禹堂.晚期肺癌与血小板增多症关系的探讨[J].中西医结合杂志,1988,8(4):276.
[20]钱彦方.活血化瘀中药对肿瘤形成和转移的影响[J].中医杂志,2008,49(10):942-945.)
[21]于瑞发,王杰,张博,等.复方水质素提取物抗抑制性肿瘤的实验研究[J].实用医药杂志,2007,24(5):599-601.)
[22]陈培丰,刘鲁明,陈震,等.参三七醇提液抑制肿瘤肝转移作用机理的研究[C].第十届全国中西医结合肿瘤学术大会论文汇编,辽宁沈阳中国中西医结合学会肿瘤专业委员会,2006:286-290.
[23]石学魁,阮殿清,陶冀,等.红花多糖对人PBMC增殖活性及分泌细胞因子的影响[J].天津中医药,2010,27(4):337-339.
[24]周阿高,张勇,蒉纲,等.不同治法中药复方对H22肝癌小鼠瘤质量和体质量及免疫功能的影响[J].中西医结合学报2008,6(1):77-82.
[25]孟琳升.中医治癌大成[M].北京科学技术出版社,1997:262.
[26]张军,尹洁,程建新.华蟾素注射液治疗妇科恶性肿瘤疗效观察[J].临床荟萃,2004,19(8):461-463.
[27]马军.急性早幼粒细胞白血病的“靶向”治疗[J].中国肿瘤,1999,8(2):80.
[28]董伟华,孔天翰,韩雪飞,等.蝎毒抗癌多肽对4种人肿瘤细胞的作用[J].河南医科大学学报,1999,34(1):52-53.
[29]王晓雪,周则卫.中药以毒攻毒抗肿瘤作用研究进展[J].医药导报,2008,27(11):1364-1366.
[30]赵园园,金锋,梁军.三氧化二砷对人胃癌耐药细胞系 SGC7901/ADM耐药逆转及凋亡诱导作用的探讨[J].中国肿瘤临床,2005,33(11):611-613.)
[31]刘成军,韦世秀,李牡艳,等.中华眼镜蛇毒诱导人类小涎腺腺样囊性癌细胞凋亡报告[J].中医杂志,2006,47(6):414.
[32]黄望香,陈建霞,罗玲,等.雄黄对白血病细胞bcl-2和Fas蛋白的表达影响的研究[J].实用医技杂志,2005,12(8):2011-2012.
[33]Lin J, DongHF, Oppenheim JJ, et al.Effects of astragali radix on the growth of different cancer cell lines [J]. World J Gastroenterol,2003,9(4): 670-673.
[34]周岱翰.中药抗肿瘤研究的评析与前景[J].新中医,2008,49(11):1-3.
[35]Xiao BH, Zhang CL, Wu X. Experin ental study on the therapeutic effect of crescent euphorbia on Lewis lung cancer in mice [J]. Zhongguo Zhong Yao Za Zhi,2006,31 (12):1002-1005.
[36]张晓娇,王雪莲,赵峰,等.鸦胆油乳抑制肺癌NCI-H460细胞的增殖及其机制[J].中国肿瘤生物治疗杂志,2011,18(5): 519-523.
[37]郭晓冬,魏品康.消痰散结方对人胃癌MKN-45裸鼠移植瘤生长及细胞增殖相关蛋白表达的影响[J].中西医结合学报,2007,5(4):432-436.
[38]张秀军,肖桂芝.细胞生物学简明教程[M].北京大学医学出版社,2010:189.
[39]翟中和,王喜忠,丁明孝.细胞生物学第3版[M].高等教育出版社,2008:443.
[40]徐永红,王学清,鞠晓华,等.土槿皮乙酸诱导人胃癌SGC7901细胞凋亡及机制[J].中国药理学通报,2008,24(5):601-60 6.
[41]李琦,王炎,范忠泽,等.丹参酮IIA及其纳米粒诱导肝癌细胞凋亡及对p38MAPK、TGFβ1信号蛋白表达的影响[J].肿瘤,2008,28(1):8-12.
[42]胡章,马润娣,于立坚.土贝母皂苷对HL-60细胞周期作用的研究[J].肿瘤防治杂志,2005, 12(3):177-179.
[43]欧阳兵,季旭明.温下方含药血清诱导肠癌细胞凋亡及对Bcl-2、p53表达的影响[J].山东中医药大学学报,200 6,30(5):382-383.
[44]叶新苗,唐峰.消瘾散对荷H22肝癌小鼠抑瘤作用的实验研究[J].中华中医药杂志,2009,24(2):202-204.
[45]袁淑兰,黄光琦,王修杰,等.丹参酮和维甲酸对人宫颈癌细胞株的体外诱导分化作用[J].中华肿瘤杂志, 1995,17(6):422-424.
[46]黄韧敏,袁淑兰,宋毅,等.丹参酮诱导HL-60细胞分化及凋亡的流式细胞术分析[J].中国肿瘤临床, 1997,24(7):500-503.
[47]梁勇,羊裔明,袁淑,等.丹参酮IIA诱导原代培养人急性早幼粒细胞自血病细胞分化[J].华西医科大学学报,2000,31(2):207
[48]毛海婷,张玲,王芸,等.淫羊霍甙抗癌作用机制的实验研究[J].中药材,2000,23(9):554.
[49]郭昱,郭霞,姚金锋,等.黄芩甙对人肝癌细胞BEL-7402增殖、凋亡和分化的影响[J].中药药理与临床,2008,24(3):21-23.
[50]郑凯,沈洪.黄芪莪术配伍药物血清对胃癌MKN45细胞增殖和分化的影响[J].辽宁中医杂志,2009,36(8): 1372-1374.
[51]Leuenroth S. Riethdorf S, Erbersdobler A, et al.Detection of human telomerase RNA in the tumour-surrounding mucosa of bladder carcinomas as a marker for premalignant transformation[J]. B JU Int,2005,96(4):553-557.
[52]Holt SE, Shay JW.Role of telomerase in cellular proliferation and cancer[J].J cell Physiol,1999,180(1):10-18.
[53]Harley CB.Telomerase and cancer therapeutics [J].Nat Rev Cancer,2008,8(3):167-179.
[54]李洁,石俊英.半枝莲对人肺巨细胞癌细胞株PG细胞端粒酶活性的影响[J].中药药理与临床,2006,22(3/4):113-114.
[55]牛英才,赵学梅,张春,等.低分子姬松茸多糖对Bel-7402细胞端粒酶-RNA mRNA表达的影响[J].时珍国医国药,2008,19(11):2630-2632.
[56]常金荣.吴茱萸碱和小蘖碱对结肠癌HT29细胞的抗癌作用及机理研究[D].广州中医药大学博士毕业论文,2007.
[57]唐发清,田道法,陈朝晖,等.益气解毒颗粒对大鼠鼻咽癌变中端粒酶和端粒酶RNA表达的影响[J].湖南医科大学学报,2001,26(4):301-304.
[58]徐文军,周小舟,徐韶敏,等.抗纤灵对HepG2细胞端粒酶抑制作用的研究[J].中国中西医结合消化杂志,2011,1(35):35-37.
[59]王晓蕾,张莲英,孔道旭,等.姜黄素对裸鼠移植瘤p21及CD44v6表达的影响[J].中国病理生理杂志,2007,23(8):1524.
[60]王婷, 郑广娟,闫实,等.罗勒多糖抗卵巢癌侵袭转移的体外实验研究[J].中国病理生理杂志,2009,25(4):661-665.
[61]华海清,沈小昆,秦叔逵,等.人参皂苷Rg3抗人肝癌细胞株侵袭和转移的实验研究[J].中国癌症杂志,2005, 15(4):326-330.
[62]李晶,刘亚娴,邢彦霞,等.启膈方对人食管癌细胞株EC109、人胃癌细胞株MGC黏附的影响[J].中国中医基础医学杂志,2007,13(6):459-460.
[63]李晶,李娜,刘亚娴,等.启膈方对人胄癌MGC细胞增殖、运动能力及分泌MMP-2、MMP-9酶活性的影响[J].中国中医药信息杂志,2010,17(6):36-38.
[64]袁波,蔡绥勍,缪慧群,等.益气败毒汤对B16黑素瘤肿瘤转移抑制基因表达的影响[J].中国皮肤性病学杂志,2009,23(4): 199-203.
[65]Lim JJ,Kang S,LeeMR, et a.l Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, Ki-67 and prognosis[J]. J Oral Pathol Med,2003,32(9):552.
[66]Vlachtsis K, Nikolaou A, Markou K, et al. Clinical and molecular prognostic factors in operable laryngeal cancer [J].Eur Arch Otorhinolaryngol,2005,262(11):890.
[67]陈刚,徐晓玉.川芎嗪和丹参对小鼠Lewis肺癌生长的抑制作用与抑制血管生成的关系[J]。中草药,2004,35(4):296-299.
[68]张妮娜,卜平,朱海杭,等.半枝莲抑制肿瘤血管生成的作用及其机制研究[J].癌症,2005,24(12):1459-1463.
[69]Stanley G,Harvey K, Jiang J,et al. Ganodum lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta 1 from prostate cancer cells [J]. Biochem Biophys Res Commun,2005,330(1):46-52.
[70]谢晶日,张杨.益气养阴活血法对胃癌前病变大鼠VEGF影响的研究[J].中医药信息,2010,27(5):97-99.
[71]孙静.益气养阴方对鸡胚尿囊膜移植瘤组织血管内皮生长因子表达的影响[J].中国临床药理学与治疗学,2009,14(3):265-268.
[72]Marzolini C, Paus E, Buclin T, et al. Polymorphisms in humanMDR1 (P-glycoprotein):recent advances and clinicalrelevance[J]. Clin Pharmacol Ther,2004,75 (1):13-33.
[73]史亦谦,邓旻,朱宁希,等.刺五加体外逆转K562/ADR细胞多药耐药性的初步研究[J].中国中医药科技,2004,11(2):93-96.
[74]苗迎秋,郑丛龙.川芎嗪逆转人乳腺癌细胞耐药株多药耐药性的实验研究[J].大连医科大学学报,2010,32(3):254-259.
[75]李贺,熊茂明,孟翔凌,等.三氧化二砷逆转肝癌细胞株HepG2/AOM多药耐药的作用[J].世界华人消化杂志,2006,14(27):2691-2694.
[76]石宇雄,黄永明,许少健,等.参麦注射液对人成骨肉瘤多药耐药细胞株R-OS-732逆转作用[J].广东医学,2006,27(8):1200-1201.
[77]王建华,夏跃胜,吴永忠,等.圣和散对胃癌SGC7901/VCR耐药细胞P-糖蛋白表达的影响[J].中国实用医药杂志,2007,2(10):80-81.
[78]Cascone T, Troiani T, Morelli MP, et al. Antiangiogenic drugs in nonsmall cell lung cancer treatment [J].Curr Opin Oncol, 2006,18 (2):151-155.
[79]王文萍.实用肿瘤转移学[M].辽宁科学技术出版社,2003,3.
[80]高进,章静波.癌的侵袭与转移基础与临床[M].科学出版社,2003.5.
[81]Machado JC et al. Oncogene,2001,20 (12):1525-1528.
[82]李伟,熊正文,李宏伟,等COX-2、E-Cad的mRNA及蛋白在乳腺浸润性导管癌中的表达及意义[J].解放军医药杂志,2011,23(4):9-12.
[83]王爱军.胃癌患者血清、骨髓及癌组织中P-和E-选择素表达的研 究[D].河北医科大学硕士论文,2004.
[84]李春海.肿瘤转移生物学标志及其临床意义[R].南京.2005.
[85]马文丽、郑文岭.分子肿瘤学[M].科学出版社,2003.
[86]陈奎生,曹学全,孙淼淼,等.组织蛋白酶B表达与食管鳞癌浸润转移的关系[J].中国肿瘤临床,2006,33(15):846-850.
[87]Garbett EA, Reed MW, Brown NJ.et al. Proteolysis in human breast and colorectal cancer[J]. Br J Cancer,1999,81(2):287-293.
[88]Hofmann UB, Westphal JR., Van Kraats AA, et al. Expression of integrin alpha(a)beta(β) correlates with activation of membrane-type matrix metalloproteinase-1 (MT1-MMP) and matrix metalloproteinase-2 (MMP-2) in human melanoma cells in vitro[J].Int J Cancer,2000,87(1):12-19.
[89]Powell WC, Knox JD, Navre M, et al. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice[J]. Cancer Res,1993,53(2):417-422.
[90]Wang B, Hsu SH, Majumder S, et al. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcino genesis by targeting TIMP3 [J]. Oncogene,2010,29(12):1787-1797.
[91]Myers TJ, Brennaman LH, Stevenson M, et al. Mitochondrial reactive oxygen species mediate GPCR-induced TACE/ ADAM 17-dependent transforming growth factor-alpha shedding[J]. Mol Biol Cell,2009,20(24):5236-5249.
[92]Matsumura Y, Hanbury D, Smith J,et al. Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells[J]. BMJ,1994,308 (6 929):619-624.
[93]岳树强,窦科峰,李开宗CD44mRNA在伴有静脉侵袭的结直肠癌中的表达及其与肝转移的关系[J].西北国防医学杂志,2002,23(6):426-428.
[94]Hanemaaijer R, Verheijen JH, Maguire TM,et al. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors[J]. Int J Cancer,2000,86(2):204-207.
[95]姜汉国,唐慰萍,李飞红,等.胃癌MMP-2、MMP-9表达及对微血管生成和肿瘤转移的影响[J].实用癌症杂志,2003,18(4):354-356.
[96]蔡相军、周晶、李庆昌,等.基质金属蛋白酶及其抑制物在大肠癌表达的定量分析[J].解放军医学杂志,2001,26(8):589-590
[97]金博,荣仕,岳欣,等.基质金属蛋白酶-2,-9及金属蛋白酶组织抑制物1基因在病变肝脏的表达[J].海军总医院学报,2006,19(4):203-208.
[98]Khokha R, Waterhouse P, Yagel S et al.Antisense RNA-reduced reduetion in murine TIMP batilaotal (BB-94) in two human colon careinoma metaltasis model[J]. Cancer Res,1995,55:3629.
[99]周可祥,吴秉铨,郑杰,等TIMP-1基因转染对人肺巨细胞癌细胞系生物学行为的影响[J].中华医学杂志,1994,74:402-405.
[100]李红梅,方伟岗,时峥,等TIMP-2基因转染对高转移性人巨细胞肺癌细胞系生物学行为的影响[J]·中华医学杂志,1997,77:652-656.
[101]牛桂莲,方伟岗,郑杰,等TIMP-3基因转染抑制人肺癌细胞系侵袋与转移的研究[J].中华病理学杂志,1998,27:421-424.
[102]王文详,陈胜喜,文继肪,等.MMP2、MMP9、TIMP1、TIMP2、和CD44V6在非小细胞肺癌中的表达及与转移、预后的关系[J].中国医学工程,2007,15(2):122-130.
[103]Liotta LA, Mandler R, Murano G, et al. Tumor cell antocrine motility factor [J]. Proc Natl Acad Sci USA,1986,83(10):3302.
[104]Takanami I, Takeuchi K, Watanabe H, et al. Significance of autocrine motility factor receptor gene expression as a prognostic factor in non-small-cell lung cancer[J]. Int J Cancer,2001,95(6) 384.
[105]Kawanishi K, Doki Y, Shiozaki H, et al. Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers[J].Am J Clin Pathol,2000,113(2):266.
[106]Silletti S,Paku S.Autocrine motility factor and extracellular matrix-Ⅱ.Degradation or remodeling of substratum components directs the motile response of tumor cells[J].Int J Cancer,1998,76:129.
[107]Jiang WG, Raz A,Douglas JA,et al. Expression of autocrine motility factor and its recptor in human breast cancer.[J].J Histochem Cytochem,2006,54:231-234.
[108]黄耀,李岩松,谢谦.乳腺癌nm23表达与淋巴结转移和预后的关系[J].广东医学,1999,20(1):27-28.
[109]盛彩霞,王丽霞.nm23和E-caderin在大肠癌的表达及意义[J].实用肿瘤学杂志,2005,19(5)334-336.
[110]王丰民,沈海波.nm23基因表达与肺癌复发、转移关系探讨[J].浙江医学,2001,23(6):321-323.
[111]马文峰,翟秀岩,长堀熏,等.抗转移基因nm23-H1在多发性肝癌中的表达[J].中国医科大学学报,2001,30(6):421-422.
[112]Fu jinmoto D,Hailat N,Mechem R.et al. Proliferation related expression 19/nm 23 nucleosid asphosphate Kinase [J]. Din Invest,1998,89(3):919-924.
[113]车国卫,周清华,朱文,等.nm23-H1基因逆转人高转移大细胞肺癌细胞L9981转移表型的分子机制[J].癌症,2005,24(3):278-284.
[114]陈基善,张雅洁,胡帅尔,等VEGF-A/VEGF-C反义脱氧寡核苷酸对乳腺癌生长及其脉管生成的影响[J].癌症,2007,26(9):972-976.
[115]周莹,魏素菊,刘巍,等VEGF、VEGF-C、Flt-4蛋白和MVD、 LVD在乳腺癌组织中的表达及临床意义[J].临床肿瘤学杂志,2006,11(3):198-205.
[116]姜忠敏,张亮,张力东,等.胃肠道间质瘤中Maspin、uPA、VEGF和VEGF-C的表达及其意义[J].临床肿瘤学杂志,2011,16(7):606-609.
[117]彭晓林,王斌全,刘涛,等VEGF-A、V EGF-C、VEGF-R3在喉癌中的表达及其与淋巴转移的关系[J].实用癌症杂志,2009,24(1):15-18.
[118]尹玉,曹立宇,李吴,等siRNA沉默VEGF基因对大肠癌细胞生物学特性的影响[J].2010,19(3):288-294.
[119]佟晓光IFN-α抑制卵巢浆液性囊腺癌增殖和腹膜转移机制的研究[D].中国医科大学博士毕业论文,2007.
[120]刘康栋.小鼠IFN-γ真核表达载体的构建和转染小鼠腹腔巨噬细胞抗肿瘤效应研究[D].郑州大学硕士毕业论文,2003.
[121]朱小东.抗血管生成促肝癌转移中IL-12b介导的机体免疫起关键作用[D].复旦大学博士毕业论文,2011.
[122]周艳艳.注射用重组改构人肿瘤坏死因子治疗人胃癌主要药效学及作用机制[D].中南大学博士毕业论文,2010.
[123]王艺蓉,自咸勇.红花的作用及机制研究进展[J].滨州医学院学报,2009,32(6):451-453.
[124]尹宏,何直升,叶阳.红花化学成分的研究[J].中草药,2001,32(9):776-777.
[125]勒玮,王亮,谭艳丽,等.红花注射液对Hela细胞体外抑制的实验研究[J].河北职工医学院学报,2007,24(2):38-39.
[126]张前,牛欣,闫妍.羟基红花黄色素A抑制新生形成的机制研究[J].北京中医药大学学报,2004,27(3):37.
[127]奚胜艳,张前,刘朝阳,等.羟基红花黄色素A对裸鼠人胃腺癌BGC-823移植瘤抑制作用的研究[J].北京中医药大学学报,2009,32(5):331-335,插页3.
[128]杨志福,梅其炳.红花有效成分及药理作用[J].西北药学杂志2001,16(3):131-133.
[129]黄虹,俞曼雷,翟世康,等.红花多糖的免活性作用[J].现代免疫学,1982,(6):7-8.
[130]何素芳,王志刚,任爱农,等.红花多糖对H::荷瘤小鼠的抑瘤作用及瘤细胞VEGF,Ki67表达的影响[J].中国中药杂志,2009,34(6):795-797.
[131]张红春.红花多糖抗肿瘤作用的免疫机理研究[D].黑龙江中医药大学硕十学位论文,2005.
[132]石学魁.红花多糖诱导人胃癌SGC-7901细胞凋亡及对AKT信号的影响[D].黑龙江中医药大学博士学位论文,2011.
[133]张晓莉.红花多糖抑制人肝癌细胞作用机制的研究[D].黑龙江中医药大学博十学位论文,2011.
[134]张晓莉,李玉婷,王亚贤,等.红花多糖的提取与含量测定[J].中国实验方剂学杂志,2010, 16(7):19-21.
[135]Canistra SA, Kansas GS, Nilloff J, et al. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H[J]. Cancer Res,1993,53(16):3830-3838.
[136]崔越宏.CD44反义寡核苷酸抑制胃癌细胞SGC7901粘附侵袭的实验研究[D].中国医科大学硕士毕业论文,2003.
[137]Nomura H, Fujimoto N, Seiki M, et al. Enhanced production of matrix metalloproteinase 2 in human gastric carcinoma [J]. Int J Cancer,1996,69(1):9.
[138]程桂丹,陆枫林.肝癌中基质金属蛋白酶及其抑制因子的研究进展[J].东南大学学报(医学版),2010,29(2):215-219.
[139]谢宗佑.内源和外源性TIMP-1基因表达对大肠癌细胞侵袭与转移性的影响[D].天津医科大学博士学位论文,2004.
[140]Alvarez OA, Carmichael DF, DeClerck YA. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases[J]. J Natl Cancer Inst.1990 Apr4; 82(7):589-95.
[141]Ikenaka Y, Yoshiji H, Kuriyama S, et al. Tissue inhibitor of metalloproteinases-1(TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model[J]. Int J Cancer.2003 Jun20; 105 (3):340-6.
[142]De Lorenzo MS, Ripoll GV, Yoshiji H, et al. Altered tumor angiogenesis and metastasis of B16 melanoma in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1. In Vivo[J].2003 Jan-Feb; 17(1):45-50.
[143]Zacchigna S, Zentilin L, Morini M, et al. AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo[J]. Cancer Gene Ther.2004 Jan;11(1):73-80.
[144]Reed MJ, Koike T, Sadoun E, et al. Inhibition of TIMP-1 enhances angiogenesis in vivo and cell migration in vitro[J]. Microvasc Res.2003 Jan;65(1):9-17.
[145]刘秀娟,迟晓丽,程肖蕊,等.自分泌运动因子受体及其配体系统的研究进展[J].军事医学科学院院刊,2007,31(5):474-478.
[146]赵静丽,季峰.胃癌细胞转移相关促移动因子研究进展[J].国际消化病杂志,2009,29(3): 178-180.
[147]姜武忠.nm23基因与肿瘤关系研究进展[J].中国现代医学杂志,2003,13(13):39-42.
[148]吴秋玲,郭继龙,卢宏达,等.水蛭、斑蝥对鸡胚绒毛尿囊膜(CAM)血管生成的影响[J].世界中西医结合杂志,2010,5(10):855-857.
[149]Folkman J. Tumor angiogenesis:therapeutic implications. N Engl J Med,1971,285(21):1182-1186.
[150]陈丽霞.中药抗肿瘤血管生成研究概况[J].中医杂志2008,49(12):1133-1135.
[151]Morris AD, Leonce S, Guilbaud N, et al. Eriochrome Black T, structurally related to suram in, inhibits angiogenesis and tumor growth in vivo[J]. Anticancer Durgs,1997,8(8):746-755.
[152]Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele[J]. Nature,1996,380(6573):435-439.
[153]Augustin HG. Antiangiogenic tumour therapy:Will it work? Trends pharmacol Sci,1998,19(2):216 -220.
[154]张春阳.血管生长抑制素和CD34在胆管癌组织中的表达及其临床意义的研究[D].中国药科大学硕士学位论文,2007.
[155]张圣林,邱法波,吴力群Th1/Th2偏移与恶性肿瘤关系的研究进展[J].细胞与分子免疫学杂志,2005,21(Supp 1):113-117.
[156]高淑清,单保恩,赵泽贞,等.四种常见海藻水溶性提取液的免疫调节活性[J].癌变·畸变·突变,2004,16(1):36-38.
[157]唐瑞峰,王曙霞,张风瑞,等.TNF-α和低氧对胰腺癌细胞表达VEGF-A、C的调节[J].中国肿瘤临床,2005,32(15):852-855.